Viral Vectors
Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene Therapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-09Jul 21, 2025
Disruptive Technology
What do you view as the most disruptive or transformational technology or development on the horizon?
Pharma's Almanac
PAO-01-23-RT-01Jan 31, 2023
CDMO
Yposkesi Selected to Produce Clinical and Large-Scale Commercial Material of Micro-Dystrophin for Genethon and Sarepta Therapeutics Program
Yposkesi
PR-M01-20-NI-015-1807Jan 09, 2020